Bicycle Therapeutics Updates Nuzefatide Pevedotin Program, EphA2 Pipeline

What Happened
Bicycle Therapeutics plc (BCYC) announced on April 20, 2026 that it issued a press release providing updates on its nuzefatide pevedotin program and its EphA2 pipeline. The company filed a Current Report on Form 8-K (Item 8.01) to disclose the press release, which is attached as Exhibit 99.1 to the filing.

Key Details

• Item reported: 8.01 (Other Events) — press release issued April 20, 2026.
• Programs mentioned: nuzefatide pevedotin program and the company’s EphA2 pipeline.
• Exhibit included: Press Release (Exhibit 99.1) attached to the Form 8-K.
• Filing does not report earnings, executive changes, or financial statements in this report.

Why It Matters
Pipeline and clinical program updates are material for investors because they inform progress, timelines, and potential regulatory or development milestones for the company’s therapeutics. This 8-K simply notifies investors that Bicycle issued a public update; investors should read the attached press release (Exhibit 99.1) for any clinical data, timeline changes, or other specifics the company disclosed.